Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 64.17B | 60.12B | 59.28B | 48.70B | 41.52B |
Gross Profit | 48.98B | 43.99B | 41.87B | 35.08B | 27.90B |
EBITDA | 25.71B | 6.91B | 21.32B | 17.90B | 10.18B |
Net Income | 17.12B | 365.00M | 14.52B | 13.05B | 7.07B |
Balance Sheet | |||||
Total Assets | 117.11B | 106.67B | 109.16B | 105.69B | 91.59B |
Cash, Cash Equivalents and Short-Term Investments | 13.69B | 7.09B | 13.19B | 8.10B | 8.05B |
Total Debt | 37.11B | 35.05B | 30.69B | 33.10B | 31.79B |
Total Liabilities | 70.73B | 69.04B | 63.10B | 67.44B | 66.18B |
Stockholders Equity | 46.31B | 37.58B | 45.99B | 38.18B | 25.32B |
Cash Flow | |||||
Free Cash Flow | 18.10B | 9.14B | 14.71B | 9.66B | 5.57B |
Operating Cash Flow | 21.47B | 13.01B | 19.09B | 14.11B | 10.25B |
Investing Cash Flow | -7.73B | -14.08B | -4.96B | -16.55B | -9.44B |
Financing Cash Flow | -7.03B | -4.81B | -9.12B | 2.59B | -2.83B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $211.08B | 12.24 | 39.31% | 3.81% | 4.40% | 654.93% | |
78 Outperform | $221.18B | 16.71 | 32.82% | 3.44% | 12.83% | -11.92% | |
78 Outperform | $223.38B | 28.65 | 19.81% | 2.14% | 15.48% | 22.70% | |
74 Outperform | $121.08B | 20.59 | 7.34% | 0.09% | -4.57% | 2.96% | |
73 Outperform | $162.01B | 27.50 | 105.67% | 3.07% | 15.59% | 56.99% | |
66 Neutral | $140.94B | 17.97 | 8.62% | 7.03% | 13.38% | ― | |
46 Neutral | C$205.70M | -3.34 | -23.14% | 2.45% | 20.79% | -0.36% |
On July 25, 2025, Merck & Co. announced a new restructuring program aimed at advancing its pipeline and launching new products, which will involve reducing certain positions and optimizing its manufacturing network. The program is expected to be completed by the end of 2027, with some manufacturing actions extending to 2029, and aims to achieve $3 billion in annual cost savings by reinvesting in strategic growth areas. In the second quarter of 2025, Merck reported a 2% decrease in total worldwide sales to $15.8 billion compared to the same period in 2024, with notable growth in KEYTRUDA sales but a significant decline in GARDASIL sales. The company also announced the acquisition of Verona Pharma and received FDA approval for ENFLONSIA, highlighting its strategic focus on innovation and growth.
The most recent analyst rating on (MRK) stock is a Buy with a $145.00 price target. To see the full list of analyst forecasts on Merck & Company stock, see the MRK Stock Forecast page.
On May 27, 2025, Merck & Co., Inc. held its Annual Meeting of Shareholders where several key decisions were made. The meeting resulted in the election of board members, approval of executive compensation, and ratification of the company’s accounting firm for 2025. However, shareholder proposals regarding human rights impact assessment, tax transparency, DEI goals in executive pay, and civil liberties in advertising services were not approved.
The most recent analyst rating on (MRK) stock is a Buy with a $145.00 price target. To see the full list of analyst forecasts on Merck & Company stock, see the MRK Stock Forecast page.